Viking Therapeutics Inc VKTX
News
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
Viking's stock pops as obesity-drug contender drags down Eli Lilly, Novo Nordisk
Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
This weight-loss ETF has performed well in its -2-
Healthcare stocks fade as obesity-drug optimism fades
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock's a buy.
Here's how investors can ride along as a major global commodity market shifts away from China
Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount
This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag
Viking Therapeutics' promising weight-loss drug data makes the company a takeover target
Viking Therapeutics' stock more than doubles as investors cheer cheap entry to weight-loss-drug craze
Viking Therapeutics may offer investors a cheap entry to the weight-loss drug craze
What to think about 'Peak 65'
Viking Therapeutics' stock rallies following early drug study data